Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
EGFR exon 19 deletion
i
Other names:
EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
1956
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
osimertinib
Sensitive: A1 - Approval
J Clin Oncol - 2 days (New B)
osimertinib
Sensitive
:
A1
J Clin Oncol - 2d
osimertinib
Sensitive: A1 - Approval
J Clin Oncol - 2 days
osimertinib
Sensitive
:
A1
J Clin Oncol - 2 days - (New B)
EGFR exon 19 deletion
Lung Adenocarcinoma
EGFR exon 19 deletion
Lung Adenocarcinoma
osimertinib
Sensitive: C1 - Off-label
Cancer Lett - 2 weeks (New D)
osimertinib
Sensitive
:
C1
Cancer Lett - 2wk
osimertinib
Sensitive: C1 - Off-label
Cancer Lett - 2 weeks
osimertinib
Sensitive
:
C1
Cancer Lett - 2 weeks - (New D)
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
erlotinib
Sensitive: A1 - Approval
erlotinib
Sensitive
:
A1
erlotinib
Sensitive: A1 - Approval
erlotinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
erlotinib + ramucirumab
Sensitive: A1 - Approval
erlotinib + ramucirumab
Sensitive
:
A1
erlotinib + ramucirumab
Sensitive: A1 - Approval
erlotinib + ramucirumab
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
bevacizumab + erlotinib
Sensitive: A2 - Guideline
bevacizumab + erlotinib
Sensitive
:
A2
bevacizumab + erlotinib
Sensitive: A2 - Guideline
bevacizumab + erlotinib
Sensitive
:
A2
EGFR exon 19 deletion
Lung Non-Squamous Non-Small Cell Cancer
EGFR exon 19 deletion
Lung Non-Squamous Non-Small Cell Cancer
osimertinib
Sensitive: A2 - Guideline
osimertinib
Sensitive
:
A2
osimertinib
Sensitive: A2 - Guideline
osimertinib
Sensitive
:
A2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR inhibitor
Sensitive: B - Late Trials
EGFR inhibitor
Sensitive
:
B
EGFR inhibitor
Sensitive: B - Late Trials
EGFR inhibitor
Sensitive
:
B
EGFR exon 19 deletion
Lung Adenocarcinoma
EGFR exon 19 deletion
Lung Adenocarcinoma
gefitinib
Sensitive: B - Late Trials
gefitinib
Sensitive
:
B
gefitinib
Sensitive: B - Late Trials
gefitinib
Sensitive
:
B
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
icotinib
Sensitive: B - Late Trials
icotinib
Sensitive
:
B
icotinib
Sensitive: B - Late Trials
icotinib
Sensitive
:
B
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
gefitinib + rivoceranib
Sensitive: B - Late Trials
gefitinib + rivoceranib
Sensitive
:
B
gefitinib + rivoceranib
Sensitive: B - Late Trials
gefitinib + rivoceranib
Sensitive
:
B
EGFR exon 19 deletion
Lung Non-Squamous Non-Small Cell Cancer
EGFR exon 19 deletion
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: B - Late Trials
bevacizumab + atezolizumab
Sensitive
:
B
bevacizumab + atezolizumab
Sensitive: B - Late Trials
bevacizumab + atezolizumab
Sensitive
:
B
EGFR exon 19 deletion
Lung Adenocarcinoma
EGFR exon 19 deletion
Lung Adenocarcinoma
afatinib
Sensitive: B - Late Trials
afatinib
Sensitive
:
B
afatinib
Sensitive: B - Late Trials
afatinib
Sensitive
:
B
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
gefitinib + ramucirumab
Sensitive: B - Late Trials
gefitinib + ramucirumab
Sensitive
:
B
gefitinib + ramucirumab
Sensitive: B - Late Trials
gefitinib + ramucirumab
Sensitive
:
B
EGFR exon 19 deletion
Lung Non-Small Cell Squamous Cancer
EGFR exon 19 deletion
Lung Non-Small Cell Squamous Cancer
EGFR inhibitor
Sensitive: B - Late Trials
EGFR inhibitor
Sensitive
:
B
EGFR inhibitor
Sensitive: B - Late Trials
EGFR inhibitor
Sensitive
:
B
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
aumolertinib
Sensitive: B - Late Trials
aumolertinib
Sensitive
:
B
aumolertinib
Sensitive: B - Late Trials
aumolertinib
Sensitive
:
B
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
furmonertinib
Sensitive: B - Late Trials
furmonertinib
Sensitive
:
B
furmonertinib
Sensitive: B - Late Trials
furmonertinib
Sensitive
:
B
EGFR exon 19 deletion
Small Cell Lung Cancer
EGFR exon 19 deletion
Small Cell Lung Cancer
gefitinib
Sensitive: C1 - Off-label
gefitinib
Sensitive
:
C1
gefitinib
Sensitive: C1 - Off-label
gefitinib
Sensitive
:
C1
EGFR exon 19 deletion
Lung Cancer
EGFR exon 19 deletion
Lung Cancer
gefitinib
Sensitive: C1 - Off-label
gefitinib
Sensitive
:
C1
gefitinib
Sensitive: C1 - Off-label
gefitinib
Sensitive
:
C1
EGFR exon 19 deletion
Small Cell Lung Cancer
EGFR exon 19 deletion
Small Cell Lung Cancer
osimertinib
Sensitive: C1 - Off-label
osimertinib
Sensitive
:
C1
osimertinib
Sensitive: C1 - Off-label
osimertinib
Sensitive
:
C1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
osimertinib + gefitinib
Sensitive: C2 – Inclusion Criteria
osimertinib + gefitinib
Sensitive
:
C2
osimertinib + gefitinib
Sensitive: C2 – Inclusion Criteria
osimertinib + gefitinib
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
anlotinib + icotinib
Sensitive: C2 – Inclusion Criteria
anlotinib + icotinib
Sensitive
:
C2
anlotinib + icotinib
Sensitive: C2 – Inclusion Criteria
anlotinib + icotinib
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
amivantamab-vmjw
Sensitive: C2 – Inclusion Criteria
amivantamab-vmjw
Sensitive
:
C2
amivantamab-vmjw
Sensitive: C2 – Inclusion Criteria
amivantamab-vmjw
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGF816
Sensitive: C2 – Inclusion Criteria
EGF816
Sensitive
:
C2
EGF816
Sensitive: C2 – Inclusion Criteria
EGF816
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
amivantamab-vmjw + lazertinib
Sensitive: C2 – Inclusion Criteria
amivantamab-vmjw + lazertinib
Sensitive
:
C2
amivantamab-vmjw + lazertinib
Sensitive: C2 – Inclusion Criteria
amivantamab-vmjw + lazertinib
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
U3-1402
Sensitive: C2 – Inclusion Criteria
U3-1402
Sensitive
:
C2
U3-1402
Sensitive: C2 – Inclusion Criteria
U3-1402
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
bevacizumab + osimertinib
Sensitive: C2 – Inclusion Criteria
bevacizumab + osimertinib
Sensitive
:
C2
bevacizumab + osimertinib
Sensitive: C2 – Inclusion Criteria
bevacizumab + osimertinib
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
tislelizumab
Sensitive: C2 – Inclusion Criteria
tislelizumab
Sensitive
:
C2
tislelizumab
Sensitive: C2 – Inclusion Criteria
tislelizumab
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
bevacizumab
Sensitive: C2 – Inclusion Criteria
bevacizumab
Sensitive
:
C2
bevacizumab
Sensitive: C2 – Inclusion Criteria
bevacizumab
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
lazertinib
Sensitive: C2 – Inclusion Criteria
lazertinib
Sensitive
:
C2
lazertinib
Sensitive: C2 – Inclusion Criteria
lazertinib
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
BBT-176
Sensitive: C2 – Inclusion Criteria
BBT-176
Sensitive
:
C2
BBT-176
Sensitive: C2 – Inclusion Criteria
BBT-176
Sensitive
:
C2
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
PD-L1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 inhibitor
Sensitive
:
C3
PD-L1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 inhibitor
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login